Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 206.84

+2.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John O'Neill who wrote (20276)	5/9/1998 7:09:00 AM
From: Henry Niman	Read Replies (2) of 32384

JO, Retin A (active ingredient is tretinoin) and Accutane (active ingredient is iso-tretinoin) both target RARs. LGND's Panretin targets RARs and RXRs while Targretin interacts primarily with RXRs. However, both are being tested for an oral treatment of psoriasis. I suspect that tretinoin and isotretinoin have too many side effects to be used orally for skin diseases (Vesinoid is an oral formulation of tretinoin, but it's only approved use thus far is for APL and side effects can be significant). LGND's most advanced RAR specific compound is LGD1550 and its use for treating cancer will be presented at ASCO (initial data from Phase I/II cancer trial).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next